CY1121944T1 - Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus - Google Patents

Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus

Info

Publication number
CY1121944T1
CY1121944T1 CY20191100727T CY191100727T CY1121944T1 CY 1121944 T1 CY1121944 T1 CY 1121944T1 CY 20191100727 T CY20191100727 T CY 20191100727T CY 191100727 T CY191100727 T CY 191100727T CY 1121944 T1 CY1121944 T1 CY 1121944T1
Authority
CY
Cyprus
Prior art keywords
staphylococcus aureus
immunization against
against staphylococcus
stabilized proteins
cysteine
Prior art date
Application number
CY20191100727T
Other languages
English (en)
Inventor
Fabio Bagnoli
Fabiana Falugi
Guido Grandi
Massimo MARIANI
Mikkel Nissum
Michele Pallaoro
Silvana Savino
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1121944T1 publication Critical patent/CY1121944T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Εξάλειψη σχηματισμού δεσμού δισουλφιδίου αντιγόνων S.aureus που περιέχουν κυστεΐνη ενισχύει σταθερότητα αντιγόνου. Η εφεύρεση παρέχει παραλλακτικές μορφές περιέχοντος κυστεΐνη αντιγόνου S.aureus με μετάλλαξη σημείου που αντικαθιστά, απαλείφει ή τροποποιεί το υπόλειμμα κυστεΐνης.
CY20191100727T 2012-08-31 2019-07-10 Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus CY1121944T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695723P 2012-08-31 2012-08-31
PCT/EP2013/067853 WO2014033190A1 (en) 2012-08-31 2013-08-29 Stabilised proteins for immunising against staphylococcus aureus

Publications (1)

Publication Number Publication Date
CY1121944T1 true CY1121944T1 (el) 2020-10-14

Family

ID=49036594

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100727T CY1121944T1 (el) 2012-08-31 2019-07-10 Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus

Country Status (15)

Country Link
US (1) US9926344B2 (el)
EP (1) EP2890394B1 (el)
JP (1) JP6435261B2 (el)
CN (2) CN110563818A (el)
CY (1) CY1121944T1 (el)
DK (1) DK2890394T3 (el)
ES (1) ES2737024T3 (el)
HR (1) HRP20191166T1 (el)
HU (1) HUE044211T2 (el)
LT (1) LT2890394T (el)
PL (1) PL2890394T3 (el)
PT (1) PT2890394T (el)
SI (1) SI2890394T1 (el)
TR (1) TR201910573T4 (el)
WO (1) WO2014033190A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140066212A (ko) * 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
CA2942450A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
WO2018089932A1 (en) 2016-11-14 2018-05-17 Lilac Solutions, Inc. Lithium extraction with coated ion exchange particles
JP6916042B2 (ja) * 2017-06-09 2021-08-11 株式会社明治 抗原特異的インターフェロンγ産生促進用組成物
AR112663A1 (es) 2017-08-02 2019-11-27 Lilac Solutions Inc Extracción de litio con perlas porosas de intercambio iónico
JP7427598B2 (ja) 2018-02-28 2024-02-05 ライラック ソリューションズ，インク． リチウム抽出用の粒子トラップを備えたイオン交換反応器
CA3166921A1 (en) 2020-01-09 2021-07-15 Lilac Solutions, Inc. Process for separating undesirable metals
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法
JP2023529444A (ja) 2020-06-09 2023-07-10 ライラック ソリューションズ，インク． スケール物質存在下におけるリチウム抽出
CA3199218A1 (en) 2020-11-20 2022-05-27 David Henry SNYDACKER Lithium production with volatile acid
AR125722A1 (es) 2021-04-23 2023-08-09 Lilac Solutions Inc Dispositivos de intercambio iónico para la extracción de litio

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS624300A (ja) * 1985-06-28 1987-01-10 Dai Ichi Seiyaku Co Ltd 改良型ヒトガンマインタ−フエロンおよびその製造方法
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5874238A (en) * 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
CN1306438A (zh) 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
GB9825421D0 (en) * 1998-11-19 1999-01-13 Isis Innovation Process for oxidising terpenes
DK1150918T3 (da) 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
KR100382239B1 (ko) * 2000-02-17 2003-04-26 주식회사 엘지생명과학 황색 포도상 구균의 변이 독소 에스이씨-에스이알, 그것의발현벡터 및 숙주세포, 그 생산방법 및 백신제조방법
DE60129432T2 (de) 2000-05-16 2008-04-17 Bolder Biotechnology, Inc., Louisville Verfahren zur rückfaltung von proteinen mit freien cysteinresten
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
NZ550152A (en) 2004-04-05 2009-04-30 Pfizer Prod Inc Microfluidized oil-in-water emulsions and vaccine compositions
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP2471550A1 (en) * 2005-10-07 2012-07-04 Health Protection Agency Proteins with improved solubility and methods for producing and using same
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
EP2510947B1 (en) * 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
AU2010352695B2 (en) * 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BR122019005883A8 (pt) * 2009-10-30 2022-10-04 Novartis Ag Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição
JP2011212008A (ja) * 2010-03-16 2011-10-27 Olympus Corp 蛍光タンパク質およびｐＨ測定方法
KR20140066212A (ko) * 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
JP2015500864A (ja) 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物

Also Published As

Publication number Publication date
ES2737024T3 (es) 2020-01-09
EP2890394B1 (en) 2019-05-01
HUE044211T2 (hu) 2019-10-28
EP2890394A1 (en) 2015-07-08
DK2890394T3 (da) 2019-07-15
US20150203542A1 (en) 2015-07-23
PL2890394T3 (pl) 2019-12-31
CN104619336A (zh) 2015-05-13
JP2015528455A (ja) 2015-09-28
US9926344B2 (en) 2018-03-27
SI2890394T1 (sl) 2019-06-28
CN110563818A (zh) 2019-12-13
LT2890394T (lt) 2019-07-25
JP6435261B2 (ja) 2018-12-05
WO2014033190A1 (en) 2014-03-06
HRP20191166T1 (hr) 2019-10-04
TR201910573T4 (tr) 2019-08-21
PT2890394T (pt) 2019-07-15

Similar Documents

Publication Publication Date Title
CY1121944T1 (el) Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CO2018013471A2 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
CL2018001000A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr.
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
BR112016022727A8 (pt) imunorreceptores específicos de claudina-6 e epítopos de células t
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2016001871A1 (es) Anticuerpos humanos para pd-1
BR112017020894A2 (pt) imunoreceptores específicos claudina-18.2 e epítopos de células t
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης